Oppenheimer analyst Justin Kim reiterated an Outperform rating and $65.00 price target on Apellis Pharmaceuticals (NASDAQ: APLS) after the company ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE